82.71
price down icon1.05%   -0.88
pre-market  プレマーケット:  84.59   1.88   +2.27%
loading
前日終値:
$83.59
開ける:
$83.59
24時間の取引高:
443.73K
Relative Volume:
0.64
時価総額:
$6.80B
収益:
$39.21M
当期純損益:
$-311.35M
株価収益率:
-22.48
EPS:
-3.6793
ネットキャッシュフロー:
$-234.34M
1週間 パフォーマンス:
-1.36%
1か月 パフォーマンス:
-3.15%
6か月 パフォーマンス:
+38.10%
1年 パフォーマンス:
+146.31%
1日の値動き範囲:
Value
$81.09
$85.11
1週間の範囲:
Value
$77.64
$85.39
52週間の値動き範囲:
Value
$28.06
$103.00

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1106)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
253
Name
Twitter
Name
次回の収益日
2026-04-30
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KYMR icon
KYMR
Kymera Therapeutics Inc
82.71 6.80B 39.21M -311.35M -234.34M -3.6793
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
424.36 107.87B 12.32B 4.34B 3.19B 16.86
REGN icon
REGN
Regeneron Pharmaceuticals Inc
702.27 73.63B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
794.70 49.42B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
301.11 40.20B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
297.49 33.06B 5.36B 287.73M 924.18M 2.5229

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-16 再開されました Jefferies Buy
2026-01-28 再開されました Barclays Overweight
2026-01-06 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-03 再開されました Guggenheim Buy
2025-10-24 繰り返されました B. Riley Securities Buy
2025-10-21 開始されました Mizuho Outperform
2025-09-18 繰り返されました H.C. Wainwright Buy
2025-09-17 開始されました Barclays Overweight
2025-09-16 開始されました RBC Capital Mkts Outperform
2025-07-30 再開されました B. Riley Securities Buy
2025-07-03 再開されました Morgan Stanley Overweight
2025-06-03 アップグレード B. Riley Securities Neutral → Buy
2025-06-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-06-02 アップグレード BofA Securities Neutral → Buy
2025-05-20 再開されました Stifel Buy
2025-03-13 開始されました Citigroup Buy
2024-12-10 開始されました BTIG Research Buy
2024-12-06 開始されました BMO Capital Markets Market Perform
2024-12-02 アップグレード Wells Fargo Equal Weight → Overweight
2024-11-18 開始されました Stephens Overweight
2024-09-09 再開されました Leerink Partners Outperform
2024-08-26 アップグレード Wolfe Research Peer Perform → Outperform
2024-04-22 開始されました Oppenheimer Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
May 05, 2026

Kymera presents preclinical data for IBD drug candidate KT-579 - Investing.com UK

May 05, 2026
pulisher
May 05, 2026

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week - Investing News Network

May 05, 2026
pulisher
May 05, 2026

Kymera presents preclinical data for IBD drug candidate KT-579 By Investing.com - Investing.com Australia

May 05, 2026
pulisher
May 05, 2026

Equities Analysts Issue Forecasts for KYMR Q2 Earnings - MarketBeat

May 05, 2026
pulisher
May 05, 2026

Oral bowel disease drug matched approved therapies in preclinical tests - Stock Titan

May 05, 2026
pulisher
May 04, 2026

Kymera Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-05-04 - Seeking Alpha

May 04, 2026
pulisher
May 04, 2026

Kymera Therapeutics Q1 2026 earnings preview - MSN

May 04, 2026
pulisher
May 04, 2026

Kymera Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq

May 04, 2026
pulisher
May 04, 2026

Kymera Therapeutics, Inc. Rings the Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq

May 04, 2026
pulisher
May 04, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance

May 04, 2026
pulisher
May 03, 2026

Understanding Momentum Shifts in (KYMR) - Stock Traders Daily

May 03, 2026
pulisher
May 02, 2026

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Kymera Therapeutics (KYMR) and Teleflex (TFX) - The Globe and Mail

May 02, 2026
pulisher
May 02, 2026

Kymera expects KT-579 phase I data in 2H 2026 while targeting KT-621 BROADEN2 enrollment completion by year-end - MSN

May 02, 2026
pulisher
May 02, 2026

Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Axsome Therapeutics (AXSM) and Kymera Therapeutics (KYMR) - The Globe and Mail

May 02, 2026
pulisher
May 02, 2026

Jennison Associates LLC Decreases Stock Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

May 02, 2026
pulisher
May 02, 2026

Kymera Therapeutics (NASDAQ:KYMR) Upgraded to Hold at Wall Street Zen - MarketBeat

May 02, 2026
pulisher
May 01, 2026

Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $119 - Moomoo

May 01, 2026
pulisher
May 01, 2026

KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration - Yahoo Finance

May 01, 2026
pulisher
May 01, 2026

HC Wainwright & Co. Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN

May 01, 2026
pulisher
May 01, 2026

Kymera Therapeutics, Inc. (KYMR) reports Q1 loss, tops revenue estimates - MSN

May 01, 2026
pulisher
May 01, 2026

Kymera Q1 2026 slides: immunology pipeline advances, revenue surges By Investing.com - Investing.com Australia

May 01, 2026
pulisher
May 01, 2026

Kymera Therapeutics Inc (KYMR) Q1 2026 Earnings Call Highlights: Strategic Partnerships and Financial Resilience - GuruFocus

May 01, 2026
pulisher
May 01, 2026

KYMR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

May 01, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results, Beats Expectations By $0.18 EPS - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

Key Risks and Forward-Looking Statements in Kymera Therapeutics, Inc. Q1 2026 10-Q Report - Minichart

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics Q1 Earnings Call Highlights - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics Reports Q1 2026 Financial Results, Highlights Pipeline Progress and $1.55B Cash Runway into 2029 - Minichart

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera shifts KT-579 data to 2H 2026, keeps KT-621 on track - MSN

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

Apr 30, 2026
pulisher
Apr 30, 2026

Earnings call transcript: Kymera Therapeutics beats Q1 2026 earnings forecasts By Investing.com - Investing.com Australia

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics (KYMR) Achieves Strong Q1 Revenue Performanc - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

Earnings call transcript: Kymera Therapeutics beats Q1 2026 earnings forecasts - Investing.com

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics Shares Fall After Q1 Loss Narrows, Collaboration Revenue Rises - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update - Investing News Network

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

Apr 30, 2026
pulisher
Apr 30, 2026

Is Kymera Therapeutics (KYMR) 418.1% Overvalued After Q1 2026 Be - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics (NASDAQ:KYMR) Soars on Q1 2026 Revenue and EPS Beat - ChartMill

Apr 30, 2026
pulisher
Apr 30, 2026

Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.88 Loss - marketscreener.com

Apr 30, 2026
pulisher
Apr 30, 2026

Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q1 Revenue $34.4M, vs. FactSet Est of $8.3M - marketscreener.com

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics (NASDAQ: KYMR) grows collaboration revenue but stays in loss - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics (NASDAQ: KYMR) Q1 2026 results and $45M Gilead milestone - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Press Release: Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

Pictet Asset Management Holding SA Has $37.79 Million Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

Kymera Therapeutics (KYMR) Q1 2026 Deepening Losses Test Bullish Revenue Growth Narrative - Sahm

Apr 30, 2026
pulisher
Apr 29, 2026

Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Stock - MarketBeat

Apr 29, 2026
pulisher
Apr 29, 2026

Kymera Therapeutics CEO Nello Mainolfi sells $2.4m in stock By Investing.com - Investing.com Nigeria

Apr 29, 2026
pulisher
Apr 29, 2026

Kymera Therapeutics CEO Nello Mainolfi sells $2.4m in stock - Investing.com

Apr 29, 2026
pulisher
Apr 29, 2026

Kymera (KYMR) CEO Mainolfi exercises options and sells 30,000 shares under 10b5-1 plan - Stock Titan

Apr 29, 2026
pulisher
Apr 29, 2026

[ARS] Kymera Therapeutics, Inc. SEC Filing - Stock Titan

Apr 29, 2026

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$28.32
price down icon 0.14%
$50.44
price up icon 0.48%
$95.50
price down icon 3.88%
$139.44
price down icon 0.41%
$147.21
price down icon 0.47%
ONC ONC
$297.49
price up icon 0.12%
大文字化:     |  ボリューム (24 時間):